Reduced activities of phospholipases A2 in platelets of drug-naive bipolar disorder patients

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author IKENAGA, Eliza Hiromi FMUSP-HC
TALIB, Leda Leme FMUSP-HC
FERREIRA, Aline Siqueira FMUSP-HC
MACHADO-VIEIRA, Rodrigo FMUSP-HC
FORLENZA, Orestes Vicente FMUSP-HC
GATTAZ, Wagner F. FMUSP-HC
dc.date.issued 2015
dc.identifier.citation BIPOLAR DISORDERS, v.17, n.1, p.97-101, 2015
dc.identifier.issn 1398-5647
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/9458
dc.description.abstract ObjectivePhospholipases A(2) (PLA(2)) comprise a family of hydrolytic enzymes that cleave membrane phospholipids and play a key role in cellular homeostasis. Alterations in enzymatic activity have been hypothesized in bipolar disorder (BD). Recent studies suggest that PLA(2) activity in platelets may reflect PLA(2) activity in the brain. The aim of this study was to determine PLA(2) activity in platelets of BD patients. MethodsWe determined the activity of PLA(2) subtypes [extracellular, calcium-dependent PLA(2) (sPLA(2)), intracellular, calcium-dependent PLA(2) (cPLA(2)), and intracellular, calcium-independent PLA(2) (iPLA(2))] by a radioenzymatic method in platelets from 20 patients with BD (15 drug-naive and five drug-free) and from 16 age- and gender-matched healthy controls. ResultsWe found that iPLA(2), cPLA(2), and sPLA(2) activities were lower in drug-naive patients with BD when compared to the control group (p=0.017, p<0.001, and p<0.001, respectively). ConclusionsReduced PLA(2) activity at the early stage of BD may disrupt brain function and increase the risk for the disease. Moreover, epidemiological studies show that patients with BD have a fivefold increased risk for developing Alzheimer's disease. Because patients with Alzheimer's disease also have reduced PLA(2) activity, the present finding of reduced PLA(2) in the BD group may be related to the risk factor for these individuals developing Alzheimer's disease in advanced age.
dc.language.iso eng
dc.publisher WILEY-BLACKWELL
dc.relation.ispartof Bipolar Disorders
dc.rights restrictedAccess
dc.subject Alzheimer's disease; biomarkers; bipolar disorder; phospholipases A(2); platelets
dc.subject.other mild cognitive impairment; a(2) activity; alzheimers-disease; developing dementia; molecular-dynamics; rat hippocampus; pla(2) activity; brain; schizophrenia; inhibition
dc.title Reduced activities of phospholipases A2 in platelets of drug-naive bipolar disorder patients
dc.type article
dc.rights.holder Copyright WILEY-BLACKWELL
dc.description.group LIM/27
dc.identifier.doi 10.1111/bdi.12229
dc.identifier.pmid 25041493
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author IKENAGA, Eliza Hiromi:HC:LIM/27
hcfmusp.author TALIB, Leda Leme:HC:IPQ
hcfmusp.author FERREIRA, Aline Siqueira:FM:
hcfmusp.author MACHADO-VIEIRA, Rodrigo:HC:LIM/27
hcfmusp.author FORLENZA, Orestes Vicente:FM:MPS
hcfmusp.author GATTAZ, Wagner F.:FM:MPS
hcfmusp.origem.id 2-s2.0-84921614071
hcfmusp.origem.id WOS:000348662900012
hcfmusp.publisher.city HOBOKEN
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Bosetti F, 2003, J NEUROCHEM, V85, P690, DOI 10.1046/j.1471-4159.2003.01701.x
· Brietzke E, 2009, J AFFECT DISORDERS, V116, P214, DOI 10.1016/j.jad.2008.12.001
· Bruscoli M, 2004, INT PSYCHOGERIATR, V16, P128
· Burke JE, 2009, J LIPID RES, V50, pS237, DOI 10.1194/jlr.R800033-JLR200
· Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
· Depp CA, 2004, BIPOLAR DISORD, V6, P343, DOI 10.1111/j.1399-5618.2004.00139.x
· Farooqui AA, 2006, PHARMACOL REV, V58, P591, DOI 10.1124/pr.58.3.7
· First MB, 2002, STRUCTURED CLIN INTE
· Forlenza OV, 2010, REV BRAS PSIQUIATR, V32, P216, DOI 10.1590/S1516-44462010005000002
· Forlenza OV, 2007, PROSTAG LEUKOTR ESS, V76, P47, DOI 10.1016/j.plefa.2006.10.002
· Gattaz WF, 2004, J NEURAL TRANSM, V111, P591, DOI 10.1007/s00702-004-0142-y
· Gattaz WF, 2014, J NEURAL TRANSM, V121, P193, DOI 10.1007/s00702-013-1088-8
· GATTAZ WF, 1987, BIOL PSYCHIAT, V22, P421, DOI 10.1016/0006-3223(87)90164-8
· GATTAZ WF, 1995, BIOL PSYCHIAT, V37, P13, DOI 10.1016/0006-3223(94)00123-K
· Gattaz WF, 2011, J PSYCHIATR RES, V45, P1617, DOI 10.1016/j.jpsychires.2011.07.005
· Gattaz WF, 1996, EUR ARCH PSY CLIN N, V246, P129, DOI 10.1007/BF02189113
· GATTAZ WF, 1995, SCHIZOPHR RES, V16, P1, DOI 10.1016/0920-9964(94)00060-L
· HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
· Kauer-Sant'Anna Marcia, 2009, Int J Neuropsychopharmacol, V12, P447, DOI 10.1017/S1461145708009310
· Kessing LV, 2004, J NEUROL NEUROSUR PS, V75, P1662, DOI 10.1136/jnnp.2003.031773
· Kessing LV, 1998, J AFFECT DISORDERS, V47, P41, DOI 10.1016/S0165-0327(97)00128-6
· Kessing LV, 2003, J AFFECT DISORDERS, V73, P261, DOI 10.1016/S0165-0327(02)00004-6
· Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5
· Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007
· LOWRY OH, 1951, J BIOL CHEM, V193, P265
· Martinez-Aran A, 2004, BIPOLAR DISORD, V6, P224, DOI 10.1111/j.1399-5618.2004.00111.x
· Martinez-Aran A, 2004, AM J PSYCHIAT, V161, P262, DOI 10.1176/appi.ajp.161.2.262
· Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868
· PETTEGREW JW, 1987, BIOL PSYCHIAT, V22, P857, DOI 10.1016/0006-3223(87)90084-9
· Ross BM, 1998, J NEUROCHEM, V70, P786
· Ross BM, 2006, BIPOLAR DISORD, V8, P265, DOI 10.1111/j.1399-5618.2006.00299.x
· Schaeffer EL, 2005, PSYCHOPHARMACOLOGY, V181, P392, DOI 10.1007/s00213-005-2256-9
· Schaeffer EL, 2011, J NEURAL TRANSM, V118, P1273, DOI 10.1007/s00702-011-0619-4
· Schaeffer EL, 2005, J NEURAL TRANSM, V112, P641, DOI 10.1007/s00702-005-0301-9
· Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011
· Schmitt A, 2001, J NEURAL TRANSM, V108, P1081, DOI 10.1007/s007020170026
· Smesny S, 2005, BIOL PSYCHIAT, V57, P399, DOI 10.1016/j.biopsych.2004.11.018
· Smesny S, 2008, J NEURAL TRANSM, V115, P1173, DOI 10.1007/s00702-008-0081-0
· Talib LL, 2012, PROSTAG LEUKOTR ESS, V86, P149, DOI 10.1016/j.plefa.2012.02.005
· Talib LL, 2013, PROSTAG LEUKOTR ESS, V89, P265, DOI 10.1016/j.plefa.2013.07.002
· Tavares H, 2003, SCHIZOPHR RES, V61, P1, DOI 10.1016/S0920-9964(02)00281-5
· TRZECIAK HI, 1995, EUR ARCH PSY CLIN N, V245, P179, DOI 10.1007/BF02193092
· vansGorp WG, 1998, ARCH GEN PSYCHIAT, V55, P41
· Zhou F, 1996, PROTEINS, V25, P12, DOI 10.1002/(SICI)1097-0134(199605)25:1<12::AID-PROT2>3.0.CO;2-M
dc.description.index MEDLINE
dc.identifier.eissn 1399-5618
hcfmusp.citation.scopus 6
hcfmusp.citation.wos 6


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics